Targeting glucokinase activation for the treatment of type 2 diabetes - A status review

Current Opinion in Drug Discovery and Development

Volumn 8, Issue 5, 2005, Pages 631-637

  Sarabu, Ramakanth ^a   Grimsby, Joseph ^b  

^a HOFFMANN LA ROCHE INC   (United States)

^b Hoffman La Roche Department of Metabolic Diseases   (United States)

Author keywords

Diabetes; Glucokinase; Glucokinase activators; Glucose horneostasis

Indexed keywords

2 CYCLOHEXYL 1 (4 METHANESULFONYLPHENYL)CYCLOPROPANECARBOXYLIC ACID 2 THIAZOLYLAMIDE; ANTIDIABETIC AGENT; ENZYME ACTIVATOR; GLUCOKINASE; GLUCOKINASE ACTIVATOR; RO 27 1674; RO 275145; RO 28 0450; RO 28 1674; RO 28 1675; UNCLASSIFIED DRUG;

COMPLEX FORMATION; CRYSTAL STRUCTURE; DIABETES MELLITUS; DRUG BINDING; DRUG MECHANISM; DRUG TARGETING; GENE MUTATION; GLUCOSE HOMEOSTASIS; HYPERINSULINEMIA; HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; X RAY ANALYSIS;

ANIMALS; DIABETES MELLITUS, TYPE 2; ENZYME ACTIVATION; GLUCOKINASE; HUMANS; HYPOGLYCEMIC AGENTS; MODELS, MOLECULAR; MOLECULAR STRUCTURE;

EID: 24044532571     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Meglasson MD, Matschinsky FM: Pancreatic islet glucose metabolism and regulation of insulin secretion. Diabetes Metab Rev (1986) 2(3-4):163-214.
2. Bell GI, Polonsky KS: Diabetes mellitus and genetically programmed defects in β-cell function. Nature (2001) 414(6865):788-791. A comprehensive review of the contribution of β-cell defects to the development of diabetes.
3. Van Schaftingen E: A protein from rat liver confers to glucokinase the property of antagonistically regulated by fructose-6-phosphate and fructose-1-phosphate. Eur J Biochem (1989) 179(1):179-184. The original paper describing the discovery of GKRP.
4. Agius L, Peak M, Newgard CB, Gomez-Foix AM, Guinovart JJ: Evidence for a role of glucose induced translocation of glucokinase in the control of hepatic glycogen synthesis. J Biol Chem (1996) 271(48):30479-30486.
5. Gloyn AL: Glucokinase (GCK) mutations in hyper- and hypoglycemia: Maturity-onset diabetes of the young, permanent neonatal diabetes and hyperinsulinemia of infancy. Hum Mutat (2003) 22(5):353-362. Provides a comprehensive listing of all known GK mutations.
6. Grimsby J, Sarabu R, Corbett WL, Haynes NE, Bizzarro FT, Coffey JW, Guertin KR, Hilliard DW, Kester RF, Mahaney PE, Marcus L et al: Allosteric activators of glucokinase: Potential role in diabetes therapy. Science (2003) 301(5631):370-373. Provides the first comprehensive disclosure of the discovery of a GKA and its biological activity.
7. Grimsby J, Matschinsky FM, Grippo JG: Discovery and actions of glucokinase activators. In: Glucokinase and Glycemic Disease - From Basics to Therapeutics. Matschinsky FM, Magnuson MA (Eds), Karger AG, Basel, Germany (2004):360-378.
8. Brocklehurst KJ, Payne VA, Davies RA, Carroll D, Vertigan HL, Wightman HJ, Alston S, Waddell ID, Leighton B, Coghlan MP, Agius L: Stimulation of hepatocyte glucose metabolism by novel small-molecule glucokinase activators. Diabetes (2004) 53(3):535-541. The first report on the discovery of aromatic-centered GK activators.
9. McKerrecher D, Allen JV, Bowker SS, Boyd S, Caulkett PW, Currie GS, Davies CD, Fenwick ML, Gaskin H, Grange E, Hargreaves RB et al: Discovery, synthesis and biological evaluation of novel glucokinase activators. Bioorg Med Chem Lett (2005) 15(8):2103-2106.
10. Leighton B, Atkinson AM, Gill D, Coope GJ, Vertigan H, Holme P, Allott C, Johnstone C, Mckerrecher D, Coghlan MP: Predicting in vivo glucose lowering efficiency by glucokinase activators - defining an exposure multiple. Diabetes (2005) 54(Suppl 1):Abs 2640-PO.
11. Kamata K, Mitsuya M, Nishimura T, Eiki J-I, Nagata Y: Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. Structure (2004) 12(3):429-438. Discloses the structure of the inactive form of GK and proposes the 'mnemonical mechanism' model to account for the co-operativity of GK in glucose kinetics.
12. Castelhano AL, Dong H, Fyfe MC, Gardner LS, Kamikozawa Y, Kurabayashi S, Nawano M, Ohashi R, Procter MJ, Qiu L, Rasamison CM et al: Glucokinase- activating ureas. Bioorg Med Chem Lett (2005) 15(5):1501-1504.
13. Efanov AM, Barrett DG, Brenner MB, Briggs SL, Delaunois A, Durbin JD, Giese U, Guo H, Radloff M, Sanz Gil G, Sewing S et al: A, novel glucokinase activator modulates pancreatic islet and hepatocyte function. Endocrinology (2005): epublished ahead of print.
14. Dunten P, Swain A, Kammlott U, Crowther R, Lukacs CM, Levin W, Reik L, Grimsby J, Corbett WL, Magnuson MA, Matschinsky FM et al: Crystal structure of human liver glucokinase bound to small-molecule allosteric activator. In: Glucokinase and Glycemic Disease - From Basics to Therapeutics. Matschinsky FM, Magnuson MA (Eds), Karger AG, Basel, Germany (2004):145-154. Provides the first publication of GKA bound to GK complex structure and presents the rationale for GKA mechanism of action.
15. Sarabu R: Anglo-Swedish Medicinal Chemistry - Second Symposium. IDrugs (2005) 8(5):384-386.
16. Storer AC, Cornish-Bowden A: Kinetic evidence for a 'mnemonical' mechanism for rat liver glucokinase. Biochem J (1977) 165(1):61-69.
17. Dunten P, Swain A, Kammlott U, Crowther R, Luckacs C, Reik L, Levin W, Matschinsky FM, Corbett WL, Grippo JF, Grimsby J: Crystal structure of glucokinase - unique features of the enzyme. Diabetes (2002) 51(Suppl 2):Abs 181-OR.